Holen Sie sich die Stockscreener-App
222.76
4.01%
8.595
Handel nachbörslich:
221.52
-1.24
-0.56%
Schlusskurs vom Vortag:
$214.16
Offen:
$216.43
24-Stunden-Volumen:
10.74M
Relative Volume:
0.53
Marktkapitalisierung:
$88.93B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-3.19B
KGV:
-27.35
EPS:
-8.1462
Netto-Cashflow:
$-1.60B
1W Leistung:
+9.93%
1M Leistung:
+9.49%
6M Leistung:
+387.23%
1J Leistung:
+801.86%
1-Tages-Spanne:
$215.35
$225.00
1-Wochen-Bereich:
$179.53
$225.00
52-Wochen-Spanne:
$22.28
$254.48
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
222.76 | 88.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
540.00 | 136.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
818.77 | 84.30B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
897.85 | 56.46B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.56 | 42.03B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2026-09-30 | Herabstufung | Citigroup | Neutral → Sell |
| 2026-09-03 | Herabstufung | Rothschild & Co Redburn | Neutral → Sell |
| 2026-08-28 | Hochstufung | Argus | Hold → Buy |
| 2026-08-25 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2026-08-19 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-08-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? - Zacks Investment Research
MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up - Zacks Investment Research
Will Moderna Soar on Nov. 6? - The Motley Fool
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility - The Motley Fool
Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool
Breakfast News: Science Strikes Back at Cancer - The Motley Fool
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Zacks Investment Research
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool
Breakfast News: A Conversation With Moderna’s CEO - The Motley Fool
American Tower (AMT) jumps 8% at the open, towering over a 385-stock board - 24/7 Wall St.
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip? - The Motley Fool
Moderna Wins Top Employer Status - Baystreet.ca
Capital Group Global Growth (CGGO) Buys $121.1 Million More Moderna on Oct. 21 - Yahoo Finance
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Chubb Breaks to a New 52-Week High at $363.95 - 24/7 Wall St.
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports - The Motley Fool
Moderna Sheds $12 Billion in a Single Session After a 14% Drop - 24/7 Wall St.
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 - The Motley Fool
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice - The Motley Fool
Moderna MRNA Breaks to a New 52-Week High at $242.08 - 24/7 Wall St.
Merck & (MRK) Stock Price, News & Analysis - 24/7 Wall St.
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? - The Motley Fool
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors. - The Motley Fool
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027? - The Motley Fool
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline - The Motley Fool
The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going - The Motley Fool
Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Australia
Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Nigeria
Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com UK
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? - The Motley Fool
Moderna Executive Stephen Hoge Announces Intent to Sell 39,145 Shares Under Rule 144 - Kalkine Media
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's Why Moderna (MRNA) Fell More Than Broader Market - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Lori Trahan Stock Trades and Disclosures - TechGraph
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell? - The Motley Fool
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Moderna surges 12.6% after hours, adding roughly $11 billion in value - 24/7 Wall St.
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock? - Zacks Investment Research
Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now? - Zacks Investment Research
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com India
Frank Baker joins IBM's board, bringing a private equity edge to a $213.5 billion tech giant - 24/7 Wall St.
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com Canada
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com UK
Moderna (MRNA) CFO has 704 shares withheld for taxes after converting a stock grant. - Stock Titan
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety - Benzinga
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Oct 15 '26 |
Option Exercise |
12.21 |
76,452 |
933,479 |
1,675,710 |
| Hoge Stephen | Officer |
Oct 15 '26 |
Proposed Sale |
220.72 |
39,145 |
8,640,033 |
0 |
| Hoge Stephen | President |
Oct 15 '26 |
Sale |
220.72 |
39,145 |
8,640,084 |
1,636,565 |
| Hoge Stephen | Officer |
Oct 14 '26 |
Proposed Sale |
213.48 |
39,224 |
8,373,519 |
0 |
| Hoge Stephen | President |
Oct 14 '26 |
Sale |
213.48 |
39,224 |
8,373,453 |
1,599,258 |
| Hoge Stephen | President |
Sep 15 '26 |
Option Exercise |
12.21 |
76,452 |
933,479 |
1,602,310 |
| Hoge Stephen | President |
Sep 15 '26 |
Sale |
146.07 |
40,281 |
5,883,846 |
1,562,029 |
| Hoge Stephen | Officer |
Sep 15 '26 |
Proposed Sale |
146.07 |
40,281 |
5,883,709 |
0 |
| Hoge Stephen | President |
Sep 14 '26 |
Option Exercise |
12.21 |
76,453 |
933,491 |
1,566,152 |
| Hoge Stephen | Officer |
Sep 14 '26 |
Proposed Sale |
144.13 |
40,294 |
5,807,746 |
0 |
0.68%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):